SG11201510011VA - Small molecule inhibitors of fibrosis - Google Patents
Small molecule inhibitors of fibrosisInfo
- Publication number
- SG11201510011VA SG11201510011VA SG11201510011VA SG11201510011VA SG11201510011VA SG 11201510011V A SG11201510011V A SG 11201510011VA SG 11201510011V A SG11201510011V A SG 11201510011VA SG 11201510011V A SG11201510011V A SG 11201510011VA SG 11201510011V A SG11201510011V A SG 11201510011VA
- Authority
- SG
- Singapore
- Prior art keywords
- fibrosis
- small molecule
- molecule inhibitors
- inhibitors
- small
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Agronomy & Crop Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832768P | 2013-06-07 | 2013-06-07 | |
| PCT/US2014/041174 WO2014197738A1 (en) | 2013-06-07 | 2014-06-05 | Small molecule inhibitors of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201510011VA true SG11201510011VA (en) | 2016-01-28 |
Family
ID=52008597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201510011VA SG11201510011VA (en) | 2013-06-07 | 2014-06-05 | Small molecule inhibitors of fibrosis |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9663499B2 (en) |
| EP (2) | EP3003038B1 (en) |
| JP (1) | JP6414831B2 (en) |
| KR (1) | KR102240329B1 (en) |
| CN (1) | CN105392364B (en) |
| AU (1) | AU2014274830B2 (en) |
| BR (1) | BR112015030203A2 (en) |
| CA (1) | CA2913634C (en) |
| CL (1) | CL2015003569A1 (en) |
| DK (1) | DK3003038T3 (en) |
| EA (1) | EA201592157A1 (en) |
| ES (2) | ES2991873T3 (en) |
| HK (1) | HK1221606A1 (en) |
| MX (1) | MX2015016783A (en) |
| PE (1) | PE20160523A1 (en) |
| PL (1) | PL3003038T3 (en) |
| PT (1) | PT3003038T (en) |
| SG (1) | SG11201510011VA (en) |
| TN (1) | TN2015000519A1 (en) |
| WO (1) | WO2014197738A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104042617A (en) | 2009-04-29 | 2014-09-17 | 阿马里纳药物爱尔兰有限公司 | Pharmaceutical Compositions Comprising Epa And A Cardiovascular Agent And Methods Of Using The Same |
| SG177254A1 (en) | 2009-06-15 | 2012-02-28 | Ian Osterloh | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| EP2646013A4 (en) | 2010-11-29 | 2014-03-26 | Amarin Pharma Inc | LOW-ERUCATION COMPOSITION AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASE IN A SUBJECT HAVING FISH ALLERGY / HYPERSENSITIVITY |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| ES2991873T3 (en) | 2013-06-07 | 2024-12-05 | Scripps Research Inst | Itraconazole analogues as fibrosis inhibitors |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| ES2879963T3 (en) * | 2014-12-10 | 2021-11-23 | Scripps Research Inst | Small molecule fibrosis inhibitors |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment for modulating gut microbiota |
| US12285464B2 (en) | 2016-04-18 | 2025-04-29 | The Trustees Of Columbia University In The City Of New York | Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (NASH) |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CN106986787A (en) * | 2017-03-30 | 2017-07-28 | 成都绿林科技有限公司 | A kind of synthetic method of posaconazole intermediate |
| CN106866459A (en) * | 2017-03-30 | 2017-06-20 | 成都绿林科技有限公司 | A kind of preparation method of antifungal drug intermediate |
| WO2019183006A1 (en) * | 2018-03-19 | 2019-09-26 | Liang Gui Bai | Methods and compositions for treating idiopathic pulmonary fibrosis |
| EP3750536A1 (en) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
| WO2020081446A1 (en) * | 2018-10-14 | 2020-04-23 | The University Of Chicago | Compositions and methods for activating nrf2-dependent gene expression |
| BR112022009189A2 (en) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | METHODS TO REDUCE THE RISK OF CARDIOVASCULAR EVENT IN A SUBJECT WITH ATRIAL FIBRILLATION AND/OR ATRIAL PALPITATION |
| CN115697339A (en) * | 2020-04-07 | 2023-02-03 | 阿马里纳药物爱尔兰有限公司 | Methods of treating and/or preventing viral infection and/or disease caused by a virus in a subject in need thereof |
| KR20240012390A (en) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | How to Reduce Your Risk of Heart Failure |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4218458A (en) * | 1978-06-23 | 1980-08-19 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4619931A (en) * | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
| US4791111A (en) * | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
| IL103558A0 (en) | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
| AU683515B2 (en) | 1993-11-19 | 1997-11-13 | Shell Internationale Research Maatschappij B.V. | Polyketone polymer composition |
| US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
| US5625064A (en) | 1995-04-19 | 1997-04-29 | Schering Corporation | Process for the preparation of triazolones |
| TW457240B (en) | 1995-04-20 | 2001-10-01 | Janssen Pharmaceutica Nv | Novel triazolones as apolipoprotein-B synthesis inhibitors |
| EP0957101A1 (en) * | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| CA2383546A1 (en) | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| CA2413878A1 (en) | 2000-06-20 | 2001-12-27 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| AU2003243354A1 (en) * | 2002-05-31 | 2003-12-19 | Transform Pharmaceuticals, Inc. | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods |
| EA017918B1 (en) | 2007-12-13 | 2013-04-30 | СИЕНА БИОТЕК С.п.А. | Hedgehog pathway antagonists and therapeutic applications thereof |
| WO2010021681A2 (en) | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| JO3182B1 (en) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | Human antibiotics with high pH generation - 2 |
| WO2011088404A1 (en) | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
| GB201015079D0 (en) * | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| WO2012047762A2 (en) * | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
| RS57377B1 (en) | 2010-12-07 | 2018-08-31 | Amira Pharmaceuticals Inc | Polycyclic lpa1 antagonist and uses thereof |
| WO2013036866A1 (en) | 2011-09-07 | 2013-03-14 | The Johns Hopkins University | Itraconazole analogs and use thereof |
| US20140050720A1 (en) | 2012-01-09 | 2014-02-20 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| ES2701076T3 (en) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells |
| US9790224B2 (en) | 2013-06-07 | 2017-10-17 | Rhizen Pharmaceuticals Sa | Dual selective PI3 delta and gamma kinase inhibitors |
| ES2991873T3 (en) | 2013-06-07 | 2024-12-05 | Scripps Research Inst | Itraconazole analogues as fibrosis inhibitors |
-
2014
- 2014-06-05 ES ES19191562T patent/ES2991873T3/en active Active
- 2014-06-05 HK HK16109962.7A patent/HK1221606A1/en unknown
- 2014-06-05 CA CA2913634A patent/CA2913634C/en active Active
- 2014-06-05 PL PL14807059T patent/PL3003038T3/en unknown
- 2014-06-05 WO PCT/US2014/041174 patent/WO2014197738A1/en not_active Ceased
- 2014-06-05 EP EP14807059.2A patent/EP3003038B1/en active Active
- 2014-06-05 BR BR112015030203A patent/BR112015030203A2/en not_active IP Right Cessation
- 2014-06-05 AU AU2014274830A patent/AU2014274830B2/en active Active
- 2014-06-05 PE PE2015002576A patent/PE20160523A1/en not_active Application Discontinuation
- 2014-06-05 DK DK14807059T patent/DK3003038T3/en active
- 2014-06-05 ES ES14807059T patent/ES2755125T3/en active Active
- 2014-06-05 TN TN2015000519A patent/TN2015000519A1/en unknown
- 2014-06-05 MX MX2015016783A patent/MX2015016783A/en unknown
- 2014-06-05 EP EP19191562.8A patent/EP3626242B1/en active Active
- 2014-06-05 CN CN201480032411.7A patent/CN105392364B/en active Active
- 2014-06-05 EA EA201592157A patent/EA201592157A1/en unknown
- 2014-06-05 KR KR1020157036822A patent/KR102240329B1/en active Active
- 2014-06-05 SG SG11201510011VA patent/SG11201510011VA/en unknown
- 2014-06-05 PT PT148070592T patent/PT3003038T/en unknown
- 2014-06-05 US US14/895,813 patent/US9663499B2/en active Active
- 2014-06-05 JP JP2016518012A patent/JP6414831B2/en active Active
-
2015
- 2015-12-07 CL CL2015003569A patent/CL2015003569A1/en unknown
-
2017
- 2017-04-14 US US15/488,206 patent/US9981956B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3003038T3 (en) | 2019-11-11 |
| US20160130258A1 (en) | 2016-05-12 |
| EP3003038A1 (en) | 2016-04-13 |
| KR102240329B1 (en) | 2021-04-14 |
| CA2913634A1 (en) | 2014-12-11 |
| PE20160523A1 (en) | 2016-05-25 |
| EP3003038B1 (en) | 2019-08-14 |
| HK1221606A1 (en) | 2017-06-09 |
| EP3626242A1 (en) | 2020-03-25 |
| CN105392364B (en) | 2018-09-14 |
| PT3003038T (en) | 2019-11-19 |
| CL2015003569A1 (en) | 2016-11-11 |
| EA201592157A1 (en) | 2016-05-31 |
| US20170217943A1 (en) | 2017-08-03 |
| EP3626242B1 (en) | 2024-08-07 |
| JP6414831B2 (en) | 2018-10-31 |
| ES2991873T3 (en) | 2024-12-05 |
| US9981956B2 (en) | 2018-05-29 |
| PL3003038T3 (en) | 2020-02-28 |
| AU2014274830A1 (en) | 2015-11-26 |
| WO2014197738A1 (en) | 2014-12-11 |
| JP2016521710A (en) | 2016-07-25 |
| AU2014274830B2 (en) | 2017-11-09 |
| CA2913634C (en) | 2022-08-09 |
| CN105392364A (en) | 2016-03-09 |
| ES2755125T3 (en) | 2020-04-21 |
| BR112015030203A2 (en) | 2017-07-25 |
| EP3003038A4 (en) | 2016-11-16 |
| MX2015016783A (en) | 2016-07-18 |
| US9663499B2 (en) | 2017-05-30 |
| TN2015000519A1 (en) | 2017-04-06 |
| KR20160029028A (en) | 2016-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201510011VA (en) | Small molecule inhibitors of fibrosis | |
| IL242453B (en) | Bipyrazole derivatives as jak inhibitors | |
| ZA201506796B (en) | Ido inhibitors | |
| IL265496A (en) | Bace1 inhibitors | |
| ZA201506156B (en) | Novel inhibitors | |
| PL3021839T3 (en) | Compositions for treatment of fibrosis | |
| EP3250036A4 (en) | Small molecule inhibitors of fibrosis | |
| EP2994124A4 (en) | INHIBITORS OF METALLO-ß-LACTAMASE-ENZYMES | |
| IL240763B (en) | Halogenopyrazoles as inhibitors of therombin | |
| ZA201507100B (en) | Synthesis of bace1 inhibitors | |
| HUP1600222A2 (en) | Small peptide inhibitors of �-amyloid toxicity | |
| ZA201508010B (en) | Inhibitors of metastasis | |
| GB201312311D0 (en) | Uses of enzyme inhibitors | |
| GB201318284D0 (en) | Construction of surfaces |